Acadia Pharmaceuticals ACAD Increase (Decrease) in Accounts Receivable and Other Operating Assets
Increase (Decrease) in Accounts Receivable and Other Operating Assets at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's increase (decrease) in accounts receivable and other operating assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Acadia Pharmaceuticals's increase (decrease) in accounts receivable and other operating assets?
- Acadia Pharmaceuticals (ACAD) reported increase (decrease) in accounts receivable and other operating assets of -$13.74M in Q1 2026.
- How has Acadia Pharmaceuticals's increase (decrease) in accounts receivable and other operating assets changed year-over-year?
- Acadia Pharmaceuticals's increase (decrease) in accounts receivable and other operating assets decreased by 781.9% year-over-year, from $2.02M to -$13.74M.